News Sentiment

LNTH sentiment intelligence

Lantheus Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 105.64 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-3.9% over one week, +1.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Lantheus Holdings (LNTH) Could Be 2% Undervalued Following Its Alzheimer Imaging Narrative

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -3.9% Price reacting lower
Trend fit Trend active 1.1% over four weeks
Fair value 34.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 30
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Investing.com 6
TradingView 6
Market source 5
Quartr 4
Simply Wall Street 3
simplywall.st 3
DirectorsTalk Interviews 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 10
Deals and strategy 2
Analyst action 2
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Simply Wall Street Direct company coverage

Lantheus Holdings (LNTH) Could Be 2% Undervalued Following Its Alzheimer Imaging Narrative

Lantheus Holdings (LNTH) is gaining attention due to strong stock performance and its Alzheimer's disease imaging franchise, despite concerns about slowing revenue and margin pressures. The company's radiodiagnostic pipeline, including an FDA label expansion for Neuraceq and the

Tone
Positive 67/100
Event
Earnings
Published
15 Jul 2026 08:12
Source
Simply Wall Street
Quartr Direct company coverage

Lantheus (LNTH) Q4 2024 earnings summary

Lantheus (LNTH) reported record FY2024 revenue of $1.534 billion, an 18.3% year-over-year increase, primarily driven by strong sales of PYLARIFY and DEFINITY. PYLARIFY achieved blockbuster status with over $1 billion in annual sales, and DEFINITY also showed double-digit growth.

Tone
Positive 72/100
Event
Earnings
Published
11 Jul 2026 06:10
Source
Quartr
Quartr Direct company coverage

Lantheus (LNTH) M&A Announcement Summary

Lantheus (LNTH) has announced an M&A deal designed to transform it into a fully integrated radiopharmaceutical leader by expanding manufacturing, broadening its pipeline, and entering new markets. The deal includes an upfront cash payment of $250 million plus up to $752.5 million

Tone
Positive 74/100
Event
Deals and strategy
Published
11 Jul 2026 02:41
Source
Quartr
Quartr Direct company coverage

Lantheus (LNTH) Q3 2025 earnings summary

Lantheus reported Q3 2025 revenue of $384 million, a modest 1.4% year-over-year increase, with adjusted EPS at $1.27 and GAAP EPS significantly lower due to a 78.8% drop in net income. The company announced a leadership transition, completed key acquisitions of Life Molecular Ima

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 02:41
Source
Quartr
Stock Traders Daily Direct company coverage

(LNTH) Movement as an Input in Quant Signal Sets

This article provides a quantitative analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 42.1:1 risk-reward short setup targeting a 12.0% downside against 0

Tone
Neutral 50/100
Event
Guidance
Published
08 Jul 2026 15:22
Source
Stock Traders Daily
AD HOC NEWS Direct company coverage

Lantheus Holdings Inc focuses on diagnostic imaging growth

Lantheus Holdings Inc (LANT) specializes in advanced diagnostic imaging agents and therapeutic solutions, primarily for cardiovascular and oncology applications in the US market. The company's strategy focuses on innovation, rigorous clinical evidence, and navigating complex regu

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:10
Source
AD HOC NEWS
GuruFocus Direct company coverage

Lantheus Holdings Inc (LNTH) Stock Down 6.4% but Still Overvalued -- GF Score: 82/100

Lantheus Holdings Inc (LNTH) shares dropped 6.4% to $102.82 but are still considered overvalued according to GuruFocus's GF Value™ which estimates its intrinsic value at $90.77. Despite a strong GF Score™ of 82/100, indicating robust fundamentals in profitability and growth, its

Tone
Negative 30/100
Event
Market update
Published
06 Jul 2026 23:40
Source
GuruFocus
Sahm Direct company coverage

Did FDA’s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings’ (LNTH) Risk Profile?

Lantheus Holdings received a Complete Response Letter from the FDA for its LNTH-2501 PET imaging kit due to third-party manufacturing facility issues, not product safety or efficacy. Concurrently, the company was added to the Russell 2000 Defensive and Growth-Defensive Indexes, i

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 04:10
Source
Sahm
Finviz Direct company coverage

LNTH - Lantheus Holdings Inc Latest SEC Filings

This article provides the latest SEC filings information for Lantheus Holdings Inc. (LNTH), along with comprehensive financial data, performance metrics, and key ratios. It includes details on the company's market capitalization, income, sales, P/E ratio, insider ownership, insti

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 16:39
Source
Finviz
Ad-hoc-news.de Direct company coverage

Lantheus Holdings Inc focuses on diagnostic imaging and radiopharmaceutical growth

Lantheus Holdings Inc is a specialized medical technology company that develops diagnostic imaging agents and radiopharmaceuticals for cardiology and oncology. The company's products help physicians visualize disease processes and improve diagnostic accuracy. Lantheus aims for lo

Tone
Positive 75/100
Event
Market update
Published
03 Jul 2026 15:04
Source
Ad-hoc-news.de
Investing.com Direct company coverage

Lantheus Holdings stock hits 52-week high at 111.52 USD

Lantheus Holdings stock reached a new 52-week high of $111.52, reflecting a strong 39.74% increase over the past year and investor confidence. This comes despite a recent FDA regulatory setback for its LNTH-2501 imaging kit due to manufacturing issues. Analysts like Citizens and

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 16:10
Source
Investing.com
DirectorsTalk Interviews Direct company coverage

Lantheus Holdings, Inc. (LNTH) Stock Analysis: Strong Buy Ratings Amid Impressive ROE and Expanding Diagnostic Portfolio

Lantheus Holdings, Inc. (LNTH) is a strong player in the healthcare sector, particularly in diagnostic and therapeutic products, indicated by its $7.15 billion market cap and robust stock performance. The company exhibits impressive financial health with a 23.48% Return on Equity

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 14:09
Source
DirectorsTalk Interviews
Simply Wall Street Direct company coverage

Lantheus Holdings (LNTH) New Product Narrative Keeps Valuation Questions In Focus

Lantheus Holdings (LNTH) shares have recently seen significant movement, prompting investors to re-evaluate the company's valuation in light of its diagnostics and radiopharmaceutical portfolio. While market ratios suggest a balanced valuation, the company is considered modestly

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 22:43
Source
Simply Wall Street
Investing.com Direct company coverage

FDA issues complete response letter for Lantheus’ NET imaging drug

The FDA has issued a Complete Response Letter for Lantheus Holdings Inc.'s NET imaging drug, LNTH-2501, due to unresolved manufacturing issues at a third-party facility. The FDA's decision is not related to the drug's safety or efficacy data. Despite this setback, Lantheus shares

Tone
Negative 40/100
Event
Market update
Published
27 Jun 2026 13:10
Source
Investing.com
TradingView Direct company coverage

Enterprise value to revenue forward of Lantheus Holdings, Inc. – NASDAQ:LNTH

This page displays the enterprise value to revenue forward for Lantheus Holdings, Inc. (NASDAQ: LNTH). It provides financial data and historical values for this specific metric. The content appears to be a financial data point from TradingView related to the company's valuation.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Lantheus Holdings, Inc. – NASDAQ:LNTH

This page displays the forward Price to Sales ratio for Lantheus Holdings, Inc. (NASDAQ:LNTH). It appears to be a financial data point from TradingView, indicating a specific valuation metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:10
Source
TradingView
Investing.com Direct company coverage

Lantheus stock falls after FDA rejects drug application

Lantheus Holdings Inc. shares dropped after the FDA issued a Complete Response Letter for its LNTH-2501 drug application, citing unresolved manufacturing issues at a third-party facility. The FDA's decision was not related to the clinical safety or efficacy data of the drug, whic

Tone
Negative 19/100
Event
Market update
Published
26 Jun 2026 21:10
Source
Investing.com
Reuters Direct company coverage

US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues

The U.S. FDA has declined to approve Lantheus Holdings' diagnostic imaging kit, LNTH-2501, for cancer tumors due to unresolved issues at a third-party manufacturing facility. This marks a setback for Lantheus, although the company stated that the FDA raised no concerns about the

Tone
Negative 38/100
Event
Market update
Published
26 Jun 2026 20:12
Source
Reuters
The Manila Times Direct company coverage

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

Lantheus announced that the FDA issued a Complete Response Letter for its New Drug Application for LNTH-2501, a diagnostic imaging agent for neuroendocrine tumors. The FDA's decision was due to unresolved manufacturing conditions at a third-party facility, not concerns about the

Tone
Negative 8/100
Event
Market update
Published
26 Jun 2026 20:10
Source
The Manila Times
TradingView Direct company coverage

Price to book forward of Lantheus Holdings Inc – XETR:0L8

This article focuses on the "Price to book forward" metric for Lantheus Holdings Inc (XETR:0L8) as presented on TradingView. It appears to be a financial data snippet or a specific page from a financial tracking platform, indicating that the market for this stock is currently clo

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Lantheus Holdings Inc Actuals & Estimates (NASDAQ:LNTH)

This article provides an overview of Lantheus Holdings, Inc. (NASDAQ:LNTH) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals and estimates for earnings and revenue, and key financial metrics

Tone
Positive 74/100
Event
Earnings
Published
26 Jun 2026 01:09
Source
TradingView
TradingView Direct company coverage

LNTH Forecast — Price Target — Prediction for 2027

This article provides a detailed analyst forecast for Lantheus Holdings, Inc. (LNTH) stock for 2027, including a price target of 107.82 USD, with a max estimate of 117.00 USD and a min estimate of 94.00 USD. It covers various financial metrics such as price performance, market ca

Tone
Positive 71/100
Event
Analyst action
Published
25 Jun 2026 14:10
Source
TradingView
Simply Wall Street Direct company coverage

Earnings Beat And Cautious Outlook Could Be A Game Changer For Lantheus Holdings (LNTH)

Lantheus Holdings (LNTH) recently surpassed Q1 analyst expectations for revenue and EPS due to strong demand for key products, while also reiterating its long-term plan. However, the company's full-year revenue guidance unexpectedly fell below analyst forecasts, indicating a caut

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 04:40
Source
Simply Wall Street
StockStory Direct company coverage

Healthcare Equipment and Supplies Stocks Q1 Teardown: Lantheus (NASDAQ:LNTH) Vs The Rest

This article analyzes the Q1 2026 earnings for healthcare equipment and supplies stocks, highlighting top performers like Lantheus (NASDAQ:LNTH) and STAAR Surgical (NASDAQ:STAA), and weaker performers such as Stryker (NYSE:SYK). It discusses industry trends, including innovation,

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 09:10
Source
StockStory
Investing.com Direct company coverage

Lantheus Holdings stock hits 52-week high at 107.99 USD By Investing.com

Lantheus Holdings Inc. (LNTH) stock reached a 52-week high of $107.99, demonstrating strong market performance with a significant year-to-date return of 59.58%. This achievement coincides with the company reporting strong Q1 2026 financial results, surpassing analyst expectations

Tone
Neutral 50/100
Event
Earnings
Published
23 Jun 2026 15:09
Source
Investing.com